- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07922590
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
A Micro-Randomized Trial to Optimize a Just-in-Time Adaptive Intervention for Alcohol Craving and Suicide Ideation
This study will develop and evaluate a brief, personalized, single-session telehealth intervention combined with a four-week just-in-time adaptive intervention (JITAI) delivered via text messaging for adults with alcohol use disorder (AUD) and suicidal thoughts and behaviors. The study includes qualitative interviews, pilot testing, and a 28-day micro-randomized trial (MRT). In the MRT phase, participants (N=75) will be repeatedly randomized multiple times per day to receive text messages targeting craving and suicide ideation or to receive no message. Outcomes include alcohol craving, suicide ideation, alcohol consumption, and engagement with intervention strategies
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Margaret M Baer, PhD
- Telefoonnummer: 567-218-3067
- E-mail: baerm@musc.edu
Studie Locaties
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29401
- Medical University of South Carolina
-
Contact:
- Margaret M Baer, PhD
- Telefoonnummer: 567-218-3067
- E-mail: baerm@musc.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older
- Meets DSM-5 criteria for current (past 6 months) Alcohol Use Disorder (mild, moderate, or severe)
- Reports at least one episode of suicidal ideation in the past 6 months
- Currently engaged in alcohol use treatment (at least monthly participation in outpatient or intensive outpatient individual or group treatment)
- Alcohol identified as primary substance of use
- Resides in the United States
- Owns a personal smartphone
- Able and willing to provide informed consent
- Co-occurring mood disorders (excluding bipolar disorder), anxiety disorders, or other substance use disorders are permitted
Exclusion Criteria:
- Current suicidal or homicidal intent
- Suicide attempt within the past 3 months
- Psychiatric hospitalization within the past 3 months
- Current or past psychotic disorder or bipolar disorder
- Alcohol withdrawal requiring medical management (e.g., CIWA-Ar score > 8)
- Inability or unwillingness to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Single arm. Groups of people are not randomized. Each person is repeated randomized.
Groups of people are not randomized. Each person is repeated randomized 112 times over 28 days to text message vs no text message. Within the text message condition, there is additional randomization to text message choice and text message language conditions. |
At four time points each day (112 time points across the 28-day study), each participant will be randomized to text message or no text message. Within the text message condition, there will be further randomization to Text Message Choice and Text Message Language conditions. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Integrated Plan Engagement
Tijdsspanne: 28-day MRT period
|
Participants will complete the following yes/no EMA item four times a day: "Since the last survey, I completed a strategy from my Integrated Plan." This item, created by the study team for this study, will assess the completion of any intervention strategy from the patient's individualized Integrated Plan during the 28 day period. |
28-day MRT period
|
|
Alcohol Craving
Tijdsspanne: 28-day MRT period
|
Participants will complete the following EMA item (on a 0-10 Likert scale) four times a day: "Since the last survey, I thought about drinking or how good a drink would make me feel." This item, drawn from a well-established measure of alcohol craving (Penn Alcohol Craving Scale) will assess craving during the 28 day period. |
28-day MRT period
|
|
Suicide Ideation
Tijdsspanne: 28-day MRT period
|
Participants will complete the following EMA item (on a 0-10 Likert scale) four times a day: "Since the last survey, I thought about killing myself." This item, drawn from a well-established interview that has also been used as a self-report measure to assess varied self-injurious thoughts and behaviors (Self-Injurious Thoughts and Behaviors Interview-Revised) will assess thoughts of suicide during the 28 day period. This item has been used previously by the PI in EMA studies. |
28-day MRT period
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Alcohol Consumption
Tijdsspanne: 28-day MRT period
|
Participants will complete the following EMA item to assess alcohol consumption four times a day: "Since the last survey, I drank __ drinks". |
28-day MRT period
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Margaret M Baer, PhD, Medical University of South Carolina
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Pro00151349
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .